TITLE

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis

AUTHOR(S)
Kamm, M. A.; Lichtenstein, G. R.; Sandborn, W. J.; Schreiber, S.; Lees, K.; Barrett, K.; Joseph, A.
PUB. DATE
July 2008
SOURCE
Gut;Jul2008, Vol. 57 Issue 7, p893
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Aim: Maintenance treatment in ulcerative colitis should be as convenient as possible, to increase the chance of compliance. MMX mesalazine is a once-daily, high-strength (1.2 g/tablet) formulation of 5-aminosalicylic acid. This study evaluated the safety and efficacy of MMX mesalazine dosed once or twice daily as maintenance therapy in patients with ulcerative colitis. Methods: This multicentre, randomised, open-label trial enrolled patients with strictly defined clinical and endoscopic remission, immediately following an episode of mild to moderate ulcerative colitis. Patients were randomised to MMX mesalazine 2.4 g/day as a single (2×1.2 g tablet) or divided dose (1×1.2 g tablet twice daily) for 12 months. Results: 174 patients (37.9%; safety population n = 459) experienced 384 adverse events, the majority of which were mild or moderate in intensity. Eighteen patients (3.9%), nine in each group, experienced a total of 22 serious adverse events (10 in the once-daily and 12 in the twice-daily group). Most serious adverse events were gastrointestinal, experienced by 5 patients in the once- daily and 4 in the twice-daily group. At month 12, 64.4% (efficacy population, n = 451) of patients in the once-daily and 68.5% of patients in the twice-daily group were in clinical and endoscopic remission (p = 0.351). At month 12, 88.9% and 93.2% in each group, respectively, had maintained clinical remission (were relapse free). Conclusions: MMX mesalazine 2.4 g/day administered as a single or divided dose demonstrated a good safety profile, was well tolerated and was effective as maintenance treatment. High clinical and endoscopic remission rates can be achieved with once-daily dosing.
ACCESSION #
32894052

 

Related Articles

  • E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided ‘Constant-care’ approach. Margarita Elkjaer // Gut;Dec2010, Vol. 59 Issue 12, p1652 

    BACKGROUND: The natural history of ulcerative colitis requires continuous monitoring of medical treatment via frequent outpatient visits. The European health authorities'' focus on e-health is increasing. Lack of easy access to inflammatory bowel disease (IBD) clinics, patients'' education and...

  • Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease.  // Inflammatory Bowel Disease Monitor;2012, Vol. 13 Issue 2, p78 

    This excellent review summarizes the current challenges in IBD clinical trials and gives a rational series of recommendations for improvements.

  • Recent Indications and Methods of Surgery for Inflammatory Bowel Disease. S. Ohki; S. Terashima; K. Sekikawa; S. Takenoshita; M. Gotoh // Current Drug Targets - Inflammation & Allergy;Jun2003, Vol. 2 Issue 2, p113 

    Inflammatory bowel disease, notably ulcerative colitis (UC) or Crohn disease (CD), is basically benign, but sometimes develops into serious or fatal cancer. While the primary therapies are medical, such as pharmacotherapy and dietetic modification, intractable, serious, and cancerous cases can...

  • What's new in inflammatory bowel disease in 2008? Baumgart, Daniel C. // World Journal of Gastroenterology;1/21/2008, Vol. 14 Issue 3, p329 

    Ulcerative colitis and Crohn's disease represent the two major forms of inflammatory bowel disease. In this highlight topic series of articles we cover the latest developments in genetics and epidemiology, intestinal physiology, mucosal immunology, mechanisms of epithelial cell injury and...

  • Ulcerative colitis. Ghosh, Subrata // BMJ: British Medical Journal (International Edition);04/22/2000, Vol. 320 Issue 7242, p1119 

    Provides information on ulcerative colitis. Clinical features and diagnosis; Etiology; Clinical management; Failure of medical management and its indications for surgery.

  • PREVALENCE AND MANAGEMENT OF INFLAMMATORY BOWEL DISEASE: DATA FROM PRIMARY CARE RECORDS, INCLUDING 5-ASA PRESCRIBING AND COMPLIANCE. Stone, M.A.; Mayberry, J.F.; Baker, R.B. // Gut;Apr2003 Supplement 1, Vol. 52, pA68 

    Background: Data from general practice (GP) records in North Tees (Rubin et al, 2000) suggested a higher prevalence of inflammatory bowel disease (IBD) than previous estimates from hospital data. Regular prescribing of 5-aminosalicylic acid (5-ASA) therapy can reduce the risk of colorectal...

  • The Role of Short-Chain Fatty Acid Metabolism in Colonic Disorders. Rabassa, Alfredo A.; Rogers, Arvey I. // American Journal of Gastroenterology;Apr1992, Vol. 87 Issue 4, p419 

    During the past decade it has become evident that colonic mucosal metabolism is more complex than previously suspected. Luminal short-chain fatty acids (SCFAs) are recognized as an essential fuel source for colonocytes, particularly in the distal colon. Their absence may explain the development...

  • The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease. Klotz, U. // European Journal of Clinical Pharmacology;Aug2000, Vol. 56 Issue 5, p353 

    Objective: To discuss the pharmacological properties of aminosalicylates and their potential value in the treatment of chronic inflammatory bowel disease (IBD). Methods: A review of clinical studies on the pharmacokinetics and mode of action of aminosalicylates is provided. In addition, the...

  • Target biopsy or step biopsy? Optimal surveillance for ulcerative colitis: a Japanese nationwide randomized controlled trial. Watanabe, Toshiaki; Ajioka, Yoichi; Matsumoto, Takayuki; Tomotsugu, Naoki; Takebayashi, Toru; Inoue, Eisuke; Iizuka, Bunei; Igarashi, Masahiro; Iwao, Yasushi; Ohtsuka, Kazuo; Kudo, Shin-ei; Kobayashi, Kiyonori; Sada, Miwa; Hirata, Ichiro; Murakami, Kazunari; Nagahori, Masakazu; Watanabe, Kenji; Hida, Nobuyuki; Ueno, Fumiaki; Tanaka, Shinji // Journal of Gastroenterology;Jan2011, Vol. 46, p11 

    Colorectal cancer is one of the complications of ulcerative colitis (UC) and the risk of cancer increases as the duration of the disease becomes longer. Surveillance colonoscopy has been considered to be important for the early detection and early treatment of colorectal cancer, especially in...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics